Skip to main content

Table 1 Phase II trials of bevacizumab in combination with chemotherapy in metastatic breast cancer

From: Antiangiogenic therapy for breast cancer

Reference Number of patients Therapy ORR (%) PFS (months)
Ramaswamy et al. [6] 27 (78% HER2-negative) B + docetaxel 52 (1st + 2nd line) 8
Chan et al. [7] 43 (21 evaluable) B + docetaxel Approximately 40 (1st line) NR
Hurvitz et al. [8] 69 (67 evaluable; HER2-negative) B + docetaxel 48 (1st line) 8 (TTP)
Perez et al. [9] 45 (HER2-negative) B + docetaxel + capecitabine 49 (1st line) 11
    69 (CBR)  
Hoelzer et al. [10] 61 (57 evaluable) B + paclitaxel 42 (1st line) 15
  58 (54 evaluable) B + paclitaxel + gemcitabine 48 20
Guardino et al. [11] 21 (17 evaluable) B + paclitaxel + gemcitabine 88 (CBR) NR
Rugo et al. [12] 46 B + ixabepilone (weekly) 50 (1st line) NR
  45 B + ixabepione (q3w) 71 NR
  32 B + paclitaxel 56 NR
Danso et al. [13] 49 (27 evaluable; HER2-negative) B + nab-paclitaxel 30 (1st line) 9
Conlin et al. [14] 72 B + nab-paclitaxel (three dosing schedules) 42 (1st line) 9 (TTP)
  54   42 6
  76   42 8
Sledge et al. [15] 103 B + capecitabine 39 (1st line) NR
Traina et al. [16] 29 B + capecitabine 31 (various; 10 pts with SD >6 months) NR
Dellapasqua et al. [17] 46 B + capecitabine + cyclophosphamide 48 (1st to 3rd line) 10 (TTP)
Rochlitz et al. [18] 41 B + pegylated liposomal doxorubicin 23 (1st line) 8
  1. Studies with ≥15 evaluable patients are included. B, bevacizumab; CBR, clinical benefit rate; NR, not reported; ORR, overall response rate; PFS, progression free survival; pts, patients; q3w, every third week; SD, stable disease; TTP, time to progression.